The Impact of the COVID-19 Pandemic on Testicular Cancer

Completed

• Conditions: COVID-19; Testicular Cancer
• Interventions: Behavioral: COVID-19 pandemic

• Registration Number: NCT05083143
• Lead Sponsor: Ankara Training and Research Hospital

Brief Summary

In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.

Detailed Description

The rapid spread of the 2019 coronavirus disease (COVID-19) caused by a novel betacoronavirus known as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had dramatic effects on individuals and health systems around the world. Beyond those infected with SARS-CoV-2,the intense demand for limited health system resources has led to reduced capacity, rapid depletion of healthcare systems and hospitals becoming a source of virus transmission.

Urology associations and reference centers have issued recommendations to inform urology care during the COVID-19 outbreak. It is essential that urologists give priority to patient safety. Potential delays in the diagnosis and treatment of urological conditions and the additional burden on healthcare resources must be balanced against the risks of exposure to COVID-19. While this situation aims to conserve healthcare resources, it has created the risk of delaying cancer treatment. As a result, the transformation of health services and the increasing interest of the public in avoiding exposure to the disease has led to a decrease in the number of hospital admissions.

The effects of the pandemic on patients with testicular cancer due to a decrease in emergency room and urology clinic admissions are not clear. During theCOVID-19 outbreak, the EAU (European Association of Urology) panel of testicular cancer published an evidence-based guideline. According to this guideline, four priority groups were formed and a certain period of delaying treatment was defined for patients in each group according to their priorities.

Study Timeline

• Study Start: 2021-07-01
• Study First Submitted: 2021-10-17
• Study First Submitted QC: 2021-10-17
• Study First Posted: 2021-10-19
• Primary Completion: 2022-03-15
• Study Completion: 2022-03-25
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-20
• Last Update Posted: 2022-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 50

Inclusion Criteria

• Patients diagnosed with testicular cancer in the urology clinic.

Exclusion Criteria

• Previous history of genitourinary system tumor
• Previous history of radiotherapy or chemotherapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COVID-19 Testicular Cancer	COVID-19 pandemic	Patients diagnosed with testicular cancer in the COVID-19 period
PreCOVID-19 Testicular Cancer	COVID-19 pandemic	Patients diagnosed with testicular cancer before the COVID-19 period

Primary Outcome Measures

Name	Time	Method
Rate of tumor stages	2 month	Rate of tumor stages in patients who diagnosed with testicular cancer

Trial Locations

Locations (1)

Ankara Training and Research Hospital; 🇹🇷 Ankara, Altindag, Turkey